BRPI0415519A - método para aumento das respostas de célula t citotóxica cd8+ e para tratamento de esclerose múltipla - Google Patents
método para aumento das respostas de célula t citotóxica cd8+ e para tratamento de esclerose múltiplaInfo
- Publication number
- BRPI0415519A BRPI0415519A BRPI0415519-0A BRPI0415519A BRPI0415519A BR PI0415519 A BRPI0415519 A BR PI0415519A BR PI0415519 A BRPI0415519 A BR PI0415519A BR PI0415519 A BRPI0415519 A BR PI0415519A
- Authority
- BR
- Brazil
- Prior art keywords
- multiple sclerosis
- cytotoxic
- increasing
- fragments
- present
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000005867 T cell response Effects 0.000 title 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical group C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 abstract 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 abstract 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 abstract 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 229940037642 autologous vaccine Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/45—Bacterial antigens
- A61K40/453—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51221203P | 2003-10-17 | 2003-10-17 | |
| PCT/US2004/034448 WO2005037309A1 (en) | 2003-10-17 | 2004-10-18 | A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0415519A true BRPI0415519A (pt) | 2006-12-26 |
Family
ID=34465326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0415519-0A BRPI0415519A (pt) | 2003-10-17 | 2004-10-18 | método para aumento das respostas de célula t citotóxica cd8+ e para tratamento de esclerose múltipla |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20080107664A1 (https=) |
| EP (1) | EP1677821B1 (https=) |
| JP (1) | JP2007509063A (https=) |
| CN (1) | CN1893971A (https=) |
| AU (1) | AU2004281817B2 (https=) |
| BR (1) | BRPI0415519A (https=) |
| CA (1) | CA2542668C (https=) |
| IL (1) | IL174935A (https=) |
| NZ (1) | NZ546552A (https=) |
| WO (1) | WO2005037309A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1677821B1 (en) * | 2003-10-17 | 2013-02-27 | Baylor College Of Medicine | A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis |
| CA2651328A1 (en) * | 2006-05-05 | 2007-11-15 | Opexa Therapeutics | T-cell vaccine |
| EP2050814A1 (en) * | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| JP2013510586A (ja) * | 2009-11-14 | 2013-03-28 | チュウ、カン−ユウ | アテローム性動脈硬化を治療及び／又は予防するための免疫調節方法及びシステム |
| RU2435556C1 (ru) * | 2010-04-23 | 2011-12-10 | Владимир Васильевич Лантух | Способ лечения дистрофических заболеваний заднего полюса глаза |
| WO2013063713A1 (zh) * | 2011-10-31 | 2013-05-10 | 鑫品生医科技股份有限公司 | 诱发产生综合免疫细胞的方法 |
| CN105085616A (zh) * | 2014-05-23 | 2015-11-25 | 上海市普陀区中心医院 | 一种氨基酸序列及其应用 |
| CN105085615A (zh) * | 2014-05-23 | 2015-11-25 | 上海市普陀区中心医院 | 一种多肽序列及其应用 |
| BR112019014406A2 (pt) * | 2017-01-20 | 2020-04-28 | Atara Biotherapeutics Inc | métodos de tratar esclerose múltipla usando células t autólogas |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69320967T2 (de) | 1992-04-09 | 1999-05-12 | Autoimmune, Inc., Lexington, Mass. | Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein |
| US6410518B1 (en) * | 1994-05-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| EP1082310A4 (en) | 1998-04-29 | 2001-09-12 | Univ Georgetown | Methods of identifying and using hla binding compounds as hla-agonists and antagonists |
| ATE438710T1 (de) * | 2001-05-15 | 2009-08-15 | Ortho Mcneil Janssen Pharm | Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen |
| US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| EP1677821B1 (en) * | 2003-10-17 | 2013-02-27 | Baylor College Of Medicine | A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis |
-
2004
- 2004-10-18 EP EP04795590A patent/EP1677821B1/en not_active Expired - Lifetime
- 2004-10-18 US US10/575,831 patent/US20080107664A1/en not_active Abandoned
- 2004-10-18 JP JP2006535420A patent/JP2007509063A/ja active Pending
- 2004-10-18 AU AU2004281817A patent/AU2004281817B2/en not_active Ceased
- 2004-10-18 BR BRPI0415519-0A patent/BRPI0415519A/pt not_active Application Discontinuation
- 2004-10-18 CN CNA2004800372329A patent/CN1893971A/zh active Pending
- 2004-10-18 WO PCT/US2004/034448 patent/WO2005037309A1/en not_active Ceased
- 2004-10-18 NZ NZ546552A patent/NZ546552A/en not_active IP Right Cessation
- 2004-10-18 CA CA2542668A patent/CA2542668C/en not_active Expired - Fee Related
-
2006
- 2006-04-11 IL IL174935A patent/IL174935A/en not_active IP Right Cessation
-
2009
- 2009-12-03 US US12/630,228 patent/US20100183546A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1677821A1 (en) | 2006-07-12 |
| AU2004281817B2 (en) | 2010-07-22 |
| CA2542668A1 (en) | 2005-04-28 |
| US20100183546A1 (en) | 2010-07-22 |
| AU2004281817A1 (en) | 2005-04-28 |
| US20080107664A1 (en) | 2008-05-08 |
| WO2005037309A1 (en) | 2005-04-28 |
| IL174935A0 (en) | 2006-08-20 |
| CA2542668C (en) | 2014-04-29 |
| NZ546552A (en) | 2009-10-30 |
| CN1893971A (zh) | 2007-01-10 |
| JP2007509063A (ja) | 2007-04-12 |
| EP1677821B1 (en) | 2013-02-27 |
| IL174935A (en) | 2012-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baxter | The origin and application of experimental autoimmune encephalomyelitis | |
| ES2924027T3 (es) | Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica | |
| BRPI0010612B8 (pt) | vacinas | |
| BRPI0414381A (pt) | composição de adjuvante, composição ou composições imunogênica(s), composição de vacina, processo para a fabricação de uma composição imunogênica, composição ou composições farmacêutica(s), kit, métodos para tratar um paciente que sofre de, ou que é suscetìvel a, um tumor, para incrementar uma resposta imune de um mamìfero a um antìgeno e para suscitar uma resposta imune em m mamìfero contra um estado de doença, usos de uma imidazoquinolina ou derivado da mesma e gm-csf e dos componentes | |
| BR0211520A (pt) | Células apresentando antìgeno, método para preparação da mesma e uso da mesma para vacinas de câncer | |
| BR112013002298A2 (pt) | complexação de ácidos nucleicos com componentes catiônicos reticulados com dissulfeto para transfecção e estimulação imunológica. | |
| BRPI0612656A8 (pt) | composição imunogênica, vacina, kit de vacina para a administração concomitante ou sequencial, processo para a produção da vacina, método de imunização de um hospedeiro humano contra doença causada por infecção de neisseria meningitidis, e, uso da composição imunogênica | |
| NZ597965A (en) | Methods of preparing and using stem cell compositions and kits comprising the same | |
| BR0214457A (pt) | métodos para o tratamento de cáncer | |
| WO2007117600A3 (en) | Combination therapy for treating autoimmune diseases | |
| BR0309809A (pt) | indução de toleráncia imunológica especìfica quanto ao antìgeno | |
| BR0316758A (pt) | Vacinas baseadas em levedura como imunoterapia | |
| BRPI0912411A8 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro. | |
| BRPI0707543B8 (pt) | composição de polipeptídeo e uso da mesma | |
| BRPI0210010B8 (pt) | imunógeno peptídico, bem como composição e aplicação compreendendo os mesmos | |
| BRPI0415519A (pt) | método para aumento das respostas de célula t citotóxica cd8+ e para tratamento de esclerose múltipla | |
| BRPI0516531A (pt) | imunoterapia de distúrbios auto-imunes | |
| BR0207399A (pt) | Método de terapia com células para o tratamento de tumores | |
| BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
| Karbach et al. | Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies | |
| Pinheiro et al. | The T-cell anergy induced by Leishmania amazonensis antigens is related with defective antigen presentation and apoptosis | |
| BR0010711A (pt) | Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes | |
| RU2013157923A (ru) | Терапия на основе модулирования иммунодоминантности | |
| Papathanasiou et al. | Pediatric stroke rehabilitation: A review of techniques facilitating motor recovery | |
| WO2010039924A3 (en) | Th1 vaccination priming for active immunotheraphy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A ANUIDADE. |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O COMBINADO COM 13, 10, 24 E 25 DA LPI |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 39/00 , C12N 5/06 Ipc: A61K 39/00 (2006.01), C12N 5/0783 (2010.01) |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |